Standard chemotherapy combination (cyclophosphamide, hydroxydaunorubicin [doxorubicin], vincristine, prednisolone [CHOP]) with 1, 3 or 6 cycles of the monoclonal anti-CD20-antibody rituximab in first line therapy of follicular non-Hodgkin's lymphoma

Trial Profile

Standard chemotherapy combination (cyclophosphamide, hydroxydaunorubicin [doxorubicin], vincristine, prednisolone [CHOP]) with 1, 3 or 6 cycles of the monoclonal anti-CD20-antibody rituximab in first line therapy of follicular non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Dec 2009 Status changed from active, no longer recruiting to completed.
    • 05 Dec 2009 Results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH 2009).
    • 05 Dec 2009 Primary endpoint 'Molecular response rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top